Mettler, Jasmin, Mueller, Horst, Voltin, Conrad-Amadeus ORCID: 0000-0002-5437-3959, Baues, Christian, Klaeser, Bernd, Moccia, Alden, Borchmann, Peter, Engert, Andreas, Kuhnert, Georg, Drzezga, Alexander, Dietlein, Markus and Kobe, Carsten (2019). Metabolic Tumor Volume for Response Prediction in Advanced-Stage Hodgkin Lymphoma. J. Nucl. Med., 60 (2). S. 207 - 212. RESTON: SOC NUCLEAR MEDICINE INC. ISSN 1535-5667

Full text not available from this repository.

Abstract

F-18-FDG PET/CT for staging Hodgkin lymphoma may allow for accurate and reliable assessment of the metabolic tumor volume (MTV) as a baseline risk factor. Our aim was to analyze the prognostic impact of MTV measurements obtained by different means in advanced-stage Hodgkin lymphoma patients treated within the German Hodgkin Study Group HD18 trial. Methods: Within HD18, 310 patients underwent F-18-FDG PET/CT scanning for staging, which was available to the central review panel for quantitative analysis. We calculated the MTV by 4 different thresholding methods and performed receiver-operating-characteristic analysis to evaluate the potential for prediction of early response determined by PET after 2 cycles (PET-2) of dose-escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP). Logistic regression was used to evaluate its prognostic value concerning progression-free survival and overall survival. Results: All of the different MTV calculations predicted PET-2 response to a moderate and comparable degree (area under the curve, 0.62-0.63; P = 0.01-0.06). With none of the measuring methods did the receiver-operating-characteristic curves point to any unique cutoffs; rather, a wide range of possible cutoffs was indicated. None of the MTV measurements was prognostic for progression-free survival (hazard ratio, 1.2-1.5; P = 0.15-0.52) or overall survival (hazard ratio, 1.0-1.5; P = 0.95-0.27). Conclusion: Baseline MTV as determined by different means is a predictive factor for early response to eBEACOPP after 2 cycles. However, value as a prognostic factor after a highly effective PET-2-adapted treatment strategy could not be observed.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Mettler, JasminUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mueller, HorstUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Voltin, Conrad-AmadeusUNSPECIFIEDorcid.org/0000-0002-5437-3959UNSPECIFIED
Baues, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Klaeser, BerndUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Moccia, AldenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Borchmann, PeterUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Engert, AndreasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuhnert, GeorgUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Drzezga, AlexanderUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Dietlein, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kobe, CarstenUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-158252
DOI: 10.2967/jnumed.118.210047
Journal or Publication Title: J. Nucl. Med.
Volume: 60
Number: 2
Page Range: S. 207 - 212
Date: 2019
Publisher: SOC NUCLEAR MEDICINE INC
Place of Publication: RESTON
ISSN: 1535-5667
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY; ADAPTED TREATMENT; OPEN-LABEL; CHEMOTHERAPY; PHASE-3; PET/CT; SCANMultiple languages
Radiology, Nuclear Medicine & Medical ImagingMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/15825

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item